Fuel Supply Plan Sample Clauses

Fuel Supply Plan. Upon reasonable written request of RUS, the Borrower will provide to RUS its then current fuel supply plan for the Projects.
Sample 1Sample 2Sample 3See All (9)
AutoNDA by SimpleDocs
Fuel Supply Plan. Fuel Manager shall furnish to Owner at least forty-five (45) days prior to the first full Fuel Period after the Commencement Date and each Fuel Period thereafter, a fuel, transportation and storage supply plan (the "Fuel Supply Plan"). Fuel Manager's analysis and strategy shall incorporate a least-cost optimization of the available options to develop a Fuel Supply Plan designed to provide Owner with a low-cost Gas and Oil supply portfolio that is highly flexible and secure. Owner shall give its written approval or disapproval of the Fuel Supply Plan no later than thirty (30) days after receipt thereof from Fuel Manager. If the Fuel Supply Plan is not approved or disapproved within such 30-day period, Fuel Manager shall, in the absence of instructions to the contrary from Owner, purchase Gas and Oil in the 30-day spot market in the quantities specified by Owner's nominations pursuant to Article III, to the extent required by the Facility but not covered by Existing Agreements and Additional Agreements until such time as the Fuel Supply Plan is approved. If Owner disapproves all or any portion of the proposed Fuel Supply Plan, Owner shall provide the reasons for such disapproval in writing and Owner and Fuel Manager shall make reasonable efforts to agree on a Fuel Supply Plan. If Owner and Fuel Manager cannot agree on the Fuel Supply Plan, those elements of the Fuel Supply Plan that are in dispute shall be revised in accordance with the recommendations of Owner. However, in no event shall such revised Fuel Supply Plan require Fuel Manager to perform services that might conflict with Fuel Manager's duties under this Agreement or applicable Laws. An approved Fuel Supply Plan shall constitute authorization for Fuel Manager to enter into the transactions and agreements contemplated therein as agent on behalf of Owner in accordance with such approved Fuel Supply Plan. If Fuel Manager desires to request an amendment to an approved Fuel Supply Plan at any time, Fuel Manager shall submit a proposed revised Fuel Supply Plan for Owner's consideration, including the basis for the amendment, and Owner shall approve or disapprove the proposed revised Fuel Supply Plan in writing within thirty (30) days after submission thereof. If the proposed revised Fuel Supply Plan is not approved within such 30-day period, it shall be deemed to have been disapproved. If the proposed revised Fuel Supply Plan is disapproved within such 30-day period, Owner shall furnish Fuel Manager wit...
Sample 1
Fuel Supply Plan. Borrowers shall at all times maintain a written and current plan whose goal is to cause SWMP to always have the Fuel Stockpile in place, or if the circumstances described in Section 8.1.18 are extant, to always have the Alternate Fuel Stockpile in place ("Fuel Supply Plan"). The Fuel Supply Plan will include discussion of fuel procurement, transportation, processing, labor, contingency plans, storage, moisture content, Abitibi relations and other matters consistent with the goal stated above. From and after the Term-Conversion Date, Borrowers shall always have either the Fuel Stockpile in place, or if the circumstances described in Section 8.1.18 are extant, shall always have the Alternate Fuel Stockpile in place.
Sample 1
Fuel Supply Plan. 11.1.1 At all times during the Operating Term, the Block shall be capable of utilizing Fuel as Scheduled by Buyer in order to produce the energy committed to Buyer under this Agreement. Buyer shall have the responsibility for procuring at its sole cost and making available at the Primary Gas Delivery Point the quantities of Fuel at the rates of delivery required to accommodate Buyer's Scheduling instructions. To determine the quantities of Fuel to be Scheduled by Buyer for transportation to the Primary Gas Delivery Point in order to satisfy Buyer's Scheduling instructions, Buyer shall calculate the Transportation Quantity. 11.1.2 Buyer shall pay, in accordance with Appendix B, for all Fuel used to generate energy that is delivered to Buyer pursuant to the Buyer's Scheduling instructions, including energy received during periods of ramp up and ramp down. Seller shall pay for Fuel used at the Facility for all other purposes, including (but not limited to) Station Service, initial start-up, testing and synchronization of the Block, Block start-up capacity examinations and sales to third parties. Seller shall be responsible for the cost of Fuel for start-up of the Block through the operation of the Monthly Fuel Cost Adjustment under Section E of Appendix B.
Sample 1

Related to Fuel Supply Plan

  • Clinical Supply Takeda will provide to Licensee[***] the amount of TAK-385 Licensed Compound or TAK-385 Licensed Products needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan (estimated by Licensee as of the Effective Date to be [***]), solely to the extent that Takeda can supply such TAK-385 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. Licensed Compound or TAK-385 Licensed Products (a) from its supply of TAK-385 Licensed Compound or TAK-385 Licensed Products in existence as of the Effective Date and which supply can be used for its intended purposes without further re-processing (the “Initial Clinical Supply”) and (b) after retaining the amount needed by Takeda for Clinical Trials in the Takeda Territory. Takeda will also provide to Licensee, at [***] any additional supplies of TAK-385 Licensed Compound or TAK-385 Licensed Products in excess of the Initial Clinical Supply needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan. Within [***] days after the Effective Date, the Parties will enter into a manufacturing and supply agreement (the “Takeda Clinical Manufacturing and Supply Agreement”), which will govern the terms and conditions of the Manufacturing and supply of the TAK-385 Licensed Compound and TAK-385 Licensed Products (including the Initial Clinical Supply) by Takeda to Licensee for Development purposes, including the exact quantities and the timelines for delivery. The Parties will negotiate the terms and conditions of such Takeda Clinical Manufacturing and Supply Agreement in good faith for a period of [***] days (as may be extended upon agreement of the Parties). As part of the negotiation related to the Takeda Clinical Manufacturing and Supply Agreement, the Parties shall discuss in good faith the ability of Takeda to supply to Licensee [***]. If the Parties have not entered into a definitive agreement within such negotiation period, then the final terms and conditions of such agreement will be resolved in accordance with Section 8.2 (Arbitration for Failure to Agree).

  • Commercial Supply Celgene shall Manufacture and supply all Commercial Supplies.

  • Product Supply 5.2.1 HEMISPHERX undertakes and agrees to supply to IMPATIENTS on an exclusive basis, IMPATIENTS’ requirements of Product ordered in accordance with the terms of this Agreement, for distribution and sale in the Territory, limited to EAP use of Product in accordance with Early Access Approvals.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Manufacturing Services Jabil will manufacture the Product in accordance with the Specifications and any applicable Build Schedules. Jabil will reply to each proposed Build Schedule that is submitted in accordance with the terms of this Agreement by notifying Company of its acceptance or rejection within three (3) business days of receipt of any proposed Build Schedule. In the event of Jabil’s rejection of a proposed Build Schedule, Jabil’s notice of rejection will specify the basis for such rejection. When requested by Company, and subject to appropriate fee and cost adjustments, Jabil will provide Additional Services for existing or future Product manufactured by Jabil. Company shall be solely responsible for the sufficiency and adequacy of the Specifications [***].

  • Project Plan Based on the Project Specifications, Omnicare CR has provided a description of services to be performed for Sponsor’s “A multi-center, randomized, double-blind, double-dummy, vehicle-controlled sequential cohort study to determine the safety of PEP005 0.025% and 0.05% topical gel in patients with actinic keratoses” (hereinafter “the Project”) and associated costs. Changes made in the Project scope, at any time during the Project, will result in a corresponding adjustment to the Project costs.

  • Disaster Recovery Plan Upon Tesla’s request, Supplier shall provide to Tesla reasonable information describing its disaster recovery plan that includes emergency back-up capacity, and appropriate record protection and recovery.

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Manufacturing and Supply Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field.

  • Product Quality (a) Tesoro warrants that all Products delivered under this Agreement or any Purchaser Order shall meet the latest applicable pipeline specifications for that Product upon receipt at the applicable Terminal and contain no deleterious substances or concentrations of any contaminants that may make it or its components commercially unacceptable in general industry application. Tesoro shall not deliver to any of the Terminals any Products which: (a) would in any way be injurious to any of the Terminals; (b) would render any of the Terminals unfit for the proper storage of similar Products; (c) would contaminate or otherwise downgrade the quality of the Products stored in commingled storage; (d) may not be lawfully stored at the Terminals; or (e) otherwise do not meet applicable Product specifications for such Product that are customary in the location of the Terminal. If, however, there are Products that do not have such applicable specifications, the specifications shall be mutually agreed upon by the Parties. Should Tesoro's commingled Products not meet or exceed the minimum quality standards set forth in this Agreement or any applicable Purchase Order, Tesoro shall be liable for all loss, damage and cost incurred thereby, including damage to Products of third parties commingled with Tesoro's unfit Products.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!